Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) for Prediction of Persistent AKI and Major Adverse Kidney Events

Nuttha Lumlertgul1,2,3, Monpraween Amprai1,2, Sasipha Tachaboon2,3, Janejira Dinhuzen2,3, Sadudee Peerapornratana2,3,4,5, Stephen J Kerr6,7,8 & Nattachai Srisawat1,2,3,5,9,10,11,12

We aimed to determine whether urinary neutrophil gelatinase-associated lipocalin (uNGAL) can accurately predict persistent AKI, major adverse kidney events at 30 days (MAKE30) and 365 days (MAKE365) in hospitalized AKI patients. This is a retrospective study of adult patients who were admitted at King Chulalongkorn Memorial Hospital. We performed multivariable logistic regression for persistent AKI, MAKE30, and MAKE365. We developed equations for predicting MAKE30 and MAKE365 and divided the dataset into derivation and validation cohorts. uNGAL performance and predictive models were assessed using the area under the receiver operating characteristic curve (AROC). Among 1,322 patients with AKI, 76.9%, 45.1%, and 61.7% had persistent AKI, MAKE30, and MAKE365. The AROC were 0.75 (95% confidence interval [CI] 0.70–0.80), 0.66 (95% CI 0.61–0.71), and 0.64 (95% CI 0.59–0.70) for prediction of persistent AKI, MAKE30, and MAKE365 by uNGAL. The AROC in the validation dataset combining uNGAL with clinical covariates were 0.74 (95% CI 0.69–0.79) and 0.72 (95% CI 0.67–0.77) for MAKE30 and MAKE365. We demonstrated an association between uNGAL and persistent AKI, MAKE30, and MAKE365. Prediction models combining uNGAL can modestly predict MAKE30 and MAKE365. Therefore, uNGAL is a useful tool for improving AKI risk stratification.

Acute kidney injury (AKI) is reported in 52.9–57.3% of critically ill patients and strongly associated with increased morbidity and mortality1–3. In addition, AKI survivors have increased risk of developing chronic kidney disease (CKD), CKD progression, and end-stage kidney disease (ESRD). Factors associated with an increased risk of long-term complications include diabetes, older age, number of AKI episodes, AKI severity and serum albumin4–6. Recently, AKI duration was ascertained as another prognostic factor for short-term and long-term mortality7–10.

Novel biomarkers measured at the time of intensive care unit (ICU) admission have been reported to predict short-term and long-term outcomes. Examples include urinary neutrophil gelatinase-associated lipocalin (uNGAL), urinary interleukin-18 (IL-18), urinary kidney injury molecule-1 (KIM-1), urinary insulin-like growth factor-binding protein-7 (IGFBP-7)11–13. uNGAL is a 25-kDa protein belonging to the lipocalin family. uNGAL is produced in renal epithelia and leukocytes in response to tubular injury and systemic inflammation. High uNGAL can be used to predict AKI14–17, discriminate intrinsic AKI from pre-renal AKI18–19, predict renal non-recovery, in-hospital mortality20–22, long-term...
CKD progression, ESRD, and mortality. Previous predictive models have utilized uNGAL to predict AKI, in-hospital renal replacement therapy (RRT), or death. However, no studies have assessed the clinical utility of uNGAL for assessment of overall spectrum of outcomes ranging from in-hospital mortality, renal replacement therapy (RRT), and renal non-recovery, to survival and renal function after hospital discharge.

King Chulalongkorn Memorial Hospital has employed uNGAL test as a routine measurement in AKI patients since 2015. This study aimed to first evaluate the role of uNGAL in an adult population for predicting persistent AKI. Secondly, we aimed to assess and evaluate, using multivariable logistic regression, the usefulness of uNGAL measurement in combination with standard clinical covariates for prediction of 30-day and 365-day major adverse kidney events in a heterogeneous adult population.

Results
Population. During the study period, there were 1,607 patients with at least one uNGAL measurement; after excluding duplicates, 1,322 AKI patients were included in the analysis. In our study, baseline SCr was obtained from pre-admission values in 947 (71.6%) patients, the majority of patients in our study. We used MDRD equation back-estimation in 5.6% and the first SCr on admission in 22.8%. Among AKI patients, 23.1% were detected with transient AKI and 76.9% with persistent AKI. At 30 days, MAKE30 occurred in 45.1%. At 365 days, 1,307 patients were available for MAKE365 analysis; 61.7% had MAKE365 (Fig. 1).

Most patients were male (55%), and had a median age of 66 (IQR, 55–80) years. Baseline SCr was obtained from pre-admission values in 947 (71.6%) patients. We used MDRD equation back-estimation in 5.6% and the first SCr on admission in 22.8%. uNGAL was requested in the ward, ICU, and emergency department in 70.7%, 24.4%, and 4.9% of all patients, respectively. Indications for uNGAL request were presented in Supplementary Table 1.

Urine chemistry and uNGAL for prediction of persistent versus transient AKI. Most of the AKI population (76.9%) had persistent AKI. These patients presented more frequently with AKI stage 3, sepsis, CKD, had a higher median SCr at diagnosis, and a higher peak SCr. They were less likely to have AKI from ischemic cause compared with transient AKI patients ($p < 0.001$). Those with persistent AKI had a higher proportion of MAKE30 and MAKE365, including their individual components. At 30 days, renal recovery occurred in 55.3% of those with persistent AKI versus 77.6% of those with transient AKI ($p < 0.001$) (Table 1).

Median uNGAL concentrations in persistent AKI were 603 (IQR 124, 2004) ng/mL versus 103 (IQR 72,273) ng/mL in transient AKI ($p < 0.001$, Fig. 2A). Univariate logistic regression analysis revealed AKI staging, sepsis, chronic kidney disease, FENA, FEuric, and log uNGAL to be associated with persistent AKI ($p < 0.001$), while ischemic cause was a protective factor ($p < 0.001$). After adjusting for these covariates in a multivariate logistic regression analysis, log uNGAL remained significant (Table 2).

To compare the performance of each individual biomarker in the prediction of persistent AKI, subjects who had missing values in one or more biomarkers were excluded for ROC curve analysis. Overall, there were 446 patients with available uNGAL, uNGAL/Cr, FENA, FEuric, and log uNGAL to be associated with persistent AKI ($p < 0.001$), while ischemic cause was a protective factor ($p < 0.001$). After adjusting for these covariates in a multivariate logistic regression analysis, log uNGAL remained significant (Table 2).

To compare the performance of each individual biomarker in the prediction of persistent AKI, subjects who had missing values in one or more biomarkers were excluded for ROC curve analysis. Overall, there were 446 patients with available uNGAL, uNGAL/Cr, FENA, FEuric, and SCr collected on the same day. All studied biomarkers were significant predictors of persistent AKI. uNGAL/Cr ratio showed the best discrimination of persistent AKI versus transient AKI with an AROC of 0.76 (95% CI = 0.72–0.81), comparably to uNGAL (AROC 0.75, 95% CI = 0.70–0.80) but superior to other biomarkers (Fig. 3).
| Variables                             | Total (N = 1255) | Transient AKI (N=290) | Persistent AKI (N=965) | p-value |
|--------------------------------------|------------------|-----------------------|------------------------|---------|
| Age, years (mean ± SD)               | 66.11 ± 17.27    | 65.13 ± 17.93         | 66.40 ± 17.06          | 0.27    |
| Male (%)                             | 691 (55.1)       | 163 (56.2)            | 528 (54.7)             | 0.65    |
| Place of NGAL sent (%)               |                  |                       |                        | 0.14    |
| Ward                                 | 878 (70.2)       | 217 (74.8)            | 665 (68.9)             |         |
| ED                                   | 60 (4.8)         | 13 (4.5)              | 47 (4.9)               |         |
| ICU                                  | 313 (25.0)       | 60 (20.7)             | 253 (26.2)             |         |
| Admission diagnosis (%)              |                  |                       |                        | 0.16    |
| Cardiology                           | 256 (20.5)       | 67 (23.2)             | 189 (19.7)             |         |
| Infection                            | 296 (23.7)       | 64 (22.2)             | 232 (24.2)             |         |
| Malignancy                           | 162 (13.0)       | 37 (12.8)             | 125 (13.0)             |         |
| Trauma/Surgery                       | 60 (4.8)         | 12 (4.2)              | 48 (5.0)               |         |
| Rheumatology                         | 27 (2.2)         | 5 (1.7)               | 22 (2.3)               |         |
| Hematology                           | 51 (4.1)         | 9 (3.1)               | 42 (4.4)               |         |
| Endocrinology                        | 24 (1.9)         | 7 (2.4)               | 17 (1.8)               |         |
| Ob-Gyn                               | 4 (0.3)          | 2 (0.7)               | 2 (0.2)                |         |
| Gastroenterology                     | 104 (8.3)        | 25 (8.7)              | 79 (8.2)               |         |
| Genitourinary system                 | 72 (5.8)         | 26 (9)                | 46 (4.8)               |         |
| Respiratory system                   | 163 (13.1)       | 28 (9.7)              | 135 (14.1)             |         |
| Others                               | 29 (2.3)         | 7 (2.4)               | 22 (2.3)               |         |
| Admission type (%)                   |                  |                       |                        | 0.19    |
| Medical                              | 1,019 (81.7)     | 237 (82.0)            | 782 (81.5)             |         |
| Elective surgery                     | 129 (10.3)       | 35 (29.9)             | 94 (9.8)               |         |
| Emergency surgery                    | 100 (8.0)        | 17 (5.9)              | 83 (8.7)               |         |
| AKI staging (%)                      |                  |                       |                        | <0.001  |
| 1                                    | 443 (35.3)       | 172 (59.3)            | 271 (28.1)             |         |
| 2                                    | 279 (22.2)       | 75 (25.9)             | 204 (21.1)             |         |
| 3                                    | 533 (42.5)       | 43 (14.8)             | 490 (50.8)             |         |
| Sepsis (%)                           | 546 (43.5)       | 100 (34.5)            | 446 (46.2)             | <0.001  |
| Ischemic cause (%)                   | 672 (53.6)       | 187 (64.5)            | 485 (50.4)             | <0.001  |
| Nephrotoxic AKI (%)                  | 113 (9.0)        | 26 (9.0)              | 87 (9.0)               | 1.00    |
| CKD (%)                              | 533 (42.5)       | 90 (31.0)             | 443 (45.9)             | <0.001  |
| Comorbidities (%)                    |                  |                       |                        |         |
| Diabetes                             | 463 (36.9)       | 107 (36.9)            | 356 (36.9)             | 1.00    |
| Hypertension                         | 660 (52.6)       | 156 (53.8)            | 504 (52.2)             | 0.69    |
| Congestive heart failure             | 108 (8.6)        | 30 (10.3)             | 78 (8.1)               | 0.23    |
| Ischemic heart disease               | 55 (4.4)         | 9 (3.1)               | 46 (4.8)               | 0.23    |
| Chronic liver disease                | 196 (15.6)       | 44 (14.9)             | 152 (15.8)             | 0.81    |
| Baseline Cr, mg/dL                   | 1.5 (1.01, 2.5)  | 1.2 (0.91, 1.7)       | 1.6 (1.1, 2.7)         | <0.001  |
| Baseline GFR, mL/min/1.73 m²         | 45.5 (27.8, 70.3)| 55.8 (39.5, 73.8)     | 42.9 (25.6, 68.9)      | <0.001  |
| Cr at AKI diagnosis, mg/dL           | 2.3 (1.6, 3.4)   | 1.9 (1.5, 2.6)        | 2.6 (1.9, 3.8)         | <0.001  |
| Peak creatinine, mg/dL               | 2.9 (1.9, 4.3)   | 1.8 (1.4, 2.5)        | 3.3 (2.5, 5)           | <0.001  |
| Last GFR at day 30, mL/min/1.73 m²   | 43.2 (27.7, 65.5)| 58.7 (41.1, 79.6)     | 38.7 (23.7, 57.4)      | <0.001  |
| Urine NGAL, ng/mL                    | 376 (102, 1500)  | 103 (72, 273)         | 603 (124, 2004)        | <0.001  |
| Urine NGAL-Cr ratio, mg/mg           | 5.5 (1.8, 32.9)  | 1.7 (0.84, 9)         | 8.9 (2.5, 42.3)        | <0.001  |
| FENA, %                              | 1.7 (0.6, 3.9)   | 1.1 (0.5, 2.1)        | 2.1 (0.7, 5.1)         | <0.001  |
| FEUric, %                            | 12.4 (6.3, 22.1) | 10.6 (5.7, 14.7)      | 13.5 (6.5, 24.7)       | 0.001   |
| FEUrea, %                            | 38.4 (24.0, 50.8)| 40.3 (26.9, 49.4)     | 36.9 (23.3, 51.6)      | 0.67    |
| MAKE30 (%)                           | 573 (45.7)       | 70 (24.1)             | 503 (52.1)             | <0.001  |
| MAKE365 (%)                          | 774 (62.4)       | 113 (39.4)            | 661 (69.3)             | <0.001  |
| 30-day mortality (%)                 | 358 (28.5)       | 43 (14.8)             | 315 (32.6)             | <0.001  |
| 365-day mortality (%)                | 634 (50.5)       | 99 (34.4)             | 535 (56.1)             | <0.001  |
| 30-day RRT (%)                       | 269 (21.4)       | 23 (7.9)              | 246 (25.5)             | <0.001  |
| 365-day RRT (%)                      | 308 (24.5)       | 29 (10)               | 279 (28.9)             | <0.001  |
| Doubling of Cr at day 30 (%)         | 218 (17.4)       | 25 (8.6)              | 193 (20)               | <0.001  |

Continued
### Table 1. Comparison between urine NGAL, FENa, FEuric, and FEurea in patients with transient AKI versus persistent AKI. Values in cell is median (IQR). Abbreviations NGAL, neutrophil gelatinase-associated lipocalin; FENa, fractional excretion of sodium; FEuric, fractional excretion of uric; FEurea, fractional excretion of urea; Cr, creatinine; AKI, acute kidney injury; SD, standard deviation; ED, emergency department; ICU, intensive care unit; CKD, chronic kidney disease; GFR, glomerular filtration rate; MAKE, major adverse kidney events; RRT, renal replacement therapy.

| Variables                          | Total (N = 1255) | Transient AKI (N = 290) | Persistent AKI (N = 965) | p-value |
|------------------------------------|------------------|-------------------------|--------------------------|---------|
| Doubling of Cr at day 365 (%)      | 911 (72.6)       | 161 (55.5)              | 750 (77.7)               | <0.001  |
| Recovery at day 30 (%)             | 759 (60.5)       | 225 (77.6)              | 534 (55.3)               | <0.001  |
| Recovery at day 365 (%)            | 398 (31.7)       | 124 (42.7)              | 274 (28.4)               | <0.001  |
| Length of hospital stay, days      | 17 (9, 32)       | 13 (6,25)               | 19 (10,36)               | <0.001  |

### MAKE outcomes at 30 days.

The overall MAKE30 incidence was 45.1%. The incidence of each endpoint contributing to MAKE30 was 28.3% death, 12.0% RRT, and 4.8% persistent renal dysfunction. Median uNGAL concentration between patients with MAKE30 and without MAKE30 were 846 (IQR 176, 2907) versus 179 (IQR 96, 704) ng/mL, p < 0.001 (Fig. 2B). When comparing the performance of our multivariate logistic models for predicting MAKE30 and MAKE365, we randomized the entire dataset into training and validation datasets, representing 70% and 30% of the observations, respectively; patient characteristics between these groups comparable (Supplementary Table 2). In the training dataset, 417/925 patients developed MAKE30. Table 3 shows the results from the multivariate model for MAKE at 30 days. An increased risk of MAKE30 was associated with uNGAL concentration, male sex, patients in the ICU versus other wards, those with AKI stage 3 versus 2 and 1, with sepsis, ischemic cause of AKI, malignancy and chronic liver disease.

We used the estimates from the multivariate logistic regression model to generate a MAKE30 predictive score for every individual in the training dataset. The overall mean score was 0.24 ± 1.11. For those who developed MAKE30 the mean was 0.33 ± 1.0 compared with −0.71 ± 0.98 in those who did not (mean difference 1.04 (95%CI 0.91–1.17); P < 0.001). The AROC from this model was 0.77 (95%CI 0.73–0.80), indicating a reasonable ability of the score to discriminate between those who developed MAKE30 and those who did not. Furthermore, this AROC was significantly better than a model which included only uNGAL concentration (AROC 0.72 (95%CI 0.68–0.75); P for difference in AROC < 0.001) (Fig. 4A, Table 4). We stratified patients according to deciles of scores; Table 5 shows the observed versus expected number of patients who developed MAKE30 in each stratum. The Hosmer-Lemeshow test statistic was 5.04 (P = 0.75), indicating no evidence for lack of fit (Table 5).

When the same predictive score was calculated for the 397 patients in the validation sample (overall mean score −0.23 ± 1.10), we noted similar results. For those who developed MAKE30 the mean was 0.27 ± 1.11 compared with −0.64 ± 0.94 in those who did not (mean difference 0.91 (95%CI 0.71–1.11); P < 0.001). The AROC was 0.74 (95%CI 0.69–0.79), and the Hosmer-Lemeshow test was not significant, indicating a similar level of performance observed in the training sample.

In addition, the addition of uNGAL to the multivariate model resulted in a significant increase (P < 0.001) in AROC in the validation dataset, compared to that predicted with uNGAL alone; AROC = 0.66 (95%CI 0.61–0.71) (Fig. 4B, Table 4).

### MAKE outcomes at 365 days.

The overall MAKE365 incidence was 61.7%. TheMAKE365 incidence after excluding the patients who already had MAKE30 was 32.4%; the additional endpoints were mortality (27.9%), RRT (2.7%), and persistent renal dysfunction (1.8%). Median urinary concentration between patients with MAKE365 and without MAKE365 were 625 (IQR 136, 2265) and 137 (93, 612) ng/mL, p < 0.001 (Fig. 2C).

Results from the multivariate equation for MAKE365 in the training dataset are shown in Table 3. An increased risk of MAKE365 was associated with increasing uNGAL concentration, increasing age, an ICU admission, AKI of stage 3 versus stages 1 and 2, sepsis, malignancy, ischemic heart disease, persistent AKI and chronic liver disease. Sex and ischemic cause of renal disease that were significant in the MAKE30 model were not significant in the MAKE365 model; however, age and ischemic heart disease that were not significant in the MAKE30 model were important in the MAKE365 model. The mean predicted MAKE365 score in the training sample was 0.60 ± 1.2 (1.0 ± 1.0) in those who developed MAKE365 and −0.07 ± 1.0 in those who did not; mean difference = 1.08 (95%CI 0.94–1.22; P < 0.001). The AROC was 0.77 (95%CI 0.74–0.80), which was significantly better than the AROC with uNGAL alone (0.70 (95%CI 0.67–0.74); P < 0.001) (Fig. 5A, Table 4). The Hosmer-Lemeshow test statistic was 4.73 (P = 0.79) (Table 5).

As found with the MAKE30 outcomes, the equation derived from the multivariate model in the training dataset also performed well in the validation dataset. The mean difference in MAKE365 scores between those with and without the outcome was 0.84 (95%CI 0.62–1.05); P < 0.001. The AROC was 0.72 (95%CI 0.67–0.77), suggesting reasonable discriminative ability. This was also a significant improvement (P < 0.001) on the AROC for uNGAL alone in predicting MAKE365 (AROC = 0.64 (95%CI 0.59–0.70) (Fig. 5B). The Hosmer-Lemeshow test statistic was 4.30 (P = 0.93), suggesting good calibration. The observed and expected numbers of MAKE365 events in the training and validation datasets is shown in Table 5.

### New-onset CKD and CKD progression.

We further explored associations of uNGAL and new-onset CKD and CKD progression in patients who were alive at 1 year (n = 659). In patients without baseline CKD and were alive at 1 year (n = 370), there were a 68.9% incidence of new CKD (stage 3–5 and ESRD). Compared between
Figure 2. Box plot showing uNGAL concentration distribution between persistent versus transient AKI (A), MAKE30 versus non MAKE30 (B), and MAKE365 versus non-MAKE365 (C). The box represents the 25th and 75th percentiles and line within the box represents the median. Pairwise comparison was calculated by Mann-Whitney U test.

![Box plot showing uNGAL concentration distribution between persistent versus transient AKI (A), MAKE30 versus non MAKE30 (B), and MAKE365 versus non-MAKE365 (C).](image)

Figure 3. Area under the curve receiver operating characteristic curve for Urine NGAL, Urine NGAL to Cr ratio, FENA, FEuric, and Cr at AKI diagnosis for persistent AKI; NGAL, neutrophil gelatinase-associated lipocalin; FENA, fractional excretion of sodium; FEuric, fractional excretion of uric; Cr, creatinine; AKI, acute kidney injury.

![Area under the curve receiver operating characteristic curve for Urine NGAL, Urine NGAL to Cr ratio, FENA, FEuric, and Cr at AKI diagnosis for persistent AKI.](image)

Table 2. Univariate and multivariate logistic regression analysis for persistent AKI. Abbreviations OR, odds ratio; CI, confidence interval; uNGAL, urine neutrophil gelatinase-associated lipocalin; FENA, fractional excretion of sodium; FEuric, fractional excretion of uric; Cr, creatinine; CKD, chronic kidney disease.

|                         | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | OR (95% CI)         | P value               |
| Log uNGAL              | 1.83 (1.67,2.06)    | < 0.001               |
| Log uNGAL-Cr           | 1.71 (1.54,1.91)    | < 0.001               |
| ICU vs other wards      | 1.36 (0.99,1.87)    | 0.06                  |
| AKI stage               |                     |                       |
| 1                       | Reference           | 0.001                 |
|                         | 1.73 (1.25,2.39)    | < 0.001               |
|                         | 3.23 (2.02,10.43)   | 0.003                 |
| 2                       | Reference           | 0.001                 |
|                         | 1.63 (1.24,2.15)    | < 0.001               |
|                         | 0.96 (0.50,1.82)    | 0.90                  |
| 3                       | Reference           | 0.001                 |
|                         | 0.56 (0.43,0.73)    | < 0.001               |
|                         | 0.68 (0.36,1.28)    | 0.23                  |
| Sepsis                  | 1.89 (1.43,2.49)    | < 0.001               |
|                         | 1.38 (0.73,2.62)    | 0.33                  |
| CKD                     | 1.47 (1.31,1.66)    | < 0.001               |
|                         | 2.23 (1.50,3.32)    | < 0.001               |
| Cr at AKI diagnosis     | 1.17 (1.08,1.26)    | < 0.001               |
|                         | 1.17 (1.03,1.32)    | 0.01                  |
| FENA                    | 1.04 (1.02,1.06)    | < 0.001               |
|                         | 1.01 (0.98,1.03)    | 0.69                  |
transient AKI and persistent AKI, there were 69.1% vs 79.3% of patients who had CKD at 1 year (p = 0.006). Univariate and multivariate logistic regression revealed log e uNGAL, age, and nephrotoxic cause of AKI to be associated with CKD (Supplementary Table 5). In patients with baseline CKD (n = 289), there was a 42.9% incidence of CKD progression. Univariate logistic regression revealed log e uNGAL, persistent AKI, ischemic heart disease, AKI stage 3, and SCr at AKI diagnosis to be associated with CKD progression. Multivariate logistic regression, however, showed only uNGAL and ischemic heart disease as associated factors (Supplementary Table 6). In total, 18.2% of all patients progressed to ESRD.

**Discussion**

To our knowledge, this is the first report using urine biomarker in a large cohort of heterogeneous patients for prediction of persistent AKI, MAKE30, and MAKE365. We found that uNGAL measured at the onset of AKI was associated with persistent AKI, MAKE30, MAKE365, new-onset CKD, and CKD progression. Urinary NGAL performed better than other markers for prediction of persistent AKI. For MAKE30 and MAKE365, predictive models combining uNGAL with clinical covariates significantly enhanced predictive value of MAKE30 and MAKE365 compared with uNGAL or clinical models alone.

Persistent AKI is associated with increased ICU length of stay, time on the ventilator, readmission, and mortality8–10. Persistent AKI also displayed significantly more adverse long-term outcomes with a cumulative incidence of >60% compared with 40% in transient AKI26. Coca et al. first described urinary injury markers as predictors for AKI duration in post-cardiac surgery patients7. Our data showed that patients with persistent AKI had higher uNGAL, uNGAL/Cr ratio, FENa, FEsolute, and SCr than transient AKI. Among these biomarkers, uNGAL and uNGAL/Cr ratio were superior to other conventional biomarkers including SCr, by ROC curve analysis. These findings confirm the concept that an increase in creatinine lags for AKI diagnosis and adds little value in risk

| Table 3. Results from multivariable logistic regression model of factors associated with major adverse kidney events at 1 month (MAKE30) and 1 year (MAKE365). How to calculate the probability of the patient experiencing a major adverse kidney event within 1 month (MAKE30). For example, a female with uNGAL concentration of 2000, from ICU, with stage 2 AKI, septic, non-ischaemic cause, a malignancy, chronic liver disease and persistent AKI: MAKE30 Score = −4.04 + (loge2000*0.38) + 0.63 + 0.39 + 0.61 + 0.48 + 0.39 = 1.348. The exponential of 1.348 is 3.849, so the probability this person will develop MAKE30 is 3.849/(1+3.849) = 0.79 (79%).

| Coef. | aOR (95%CI) | P      | Coef. | aOR (95%CI) | P      |
|-------|-------------|--------|-------|-------------|--------|
| Intercept | −4.04 | −3.77 | −3.77 | −3.77 | −3.77 |
| Log, uNGAL concentration | 0.38 | 1.47 (1.32–1.63) | <0.001 | 0.34 | 1.41 (1.26–1.57) | <0.001 |
| Age, per 10 year increase | — | — | — | — | — | — |
| Male versus female | 0.27 | 1.31 (0.97–1.77) | 0.08 | 0.14 | 1.15 (1.06–1.26) | 0.001 |
| ICU vs other wards | 0.63 | 1.88 (1.33–2.67) | <0.001 | 0.30 | 1.35 (0.93–1.97) | 0.113 |
| AKI stage 3 vs 2/1 | 0.86 | 2.35 (1.73–3.21) | <0.001 | 0.52 | 1.69 (1.21–2.34) | 0.002 |
| Sepsis | 0.39 | 1.47 (1.04–2.08) | 0.03 | 0.36 | 1.43 (1.03–1.98) | 0.03 |
| Ischaemic cause | 0.32 | 1.37 (0.98–1.92) | 0.06 | — | — | — |
| Malignancy | 0.61 | 1.85 (1.18–2.9) | 0.007 | 0.75 | 2.13 (1.3–3.48) | 0.003 |
| Ischemic heart disease | — | — | — | 1.90 | 6.69 (2.41–8.56) | <0.001 |
| Persistent AKI | 0.48 | 1.61 (1.06–2.43) | 0.02 | 0.82 | 2.28 (1.55–3.35) | <0.001 |
| Chronic liver disease | 0.39 | 1.48 (0.98–2.35) | 0.06 | 0.76 | 2.14 (1.38–3.34) | 0.001 |

**Figure 4.** ROC curves from a multivariate clinical model, uNGAL, and the model with uNGAL for prediction of MAKE30 in the training dataset (A) and validation dataset (B).
AUC (95% CI)  

| MAKE30 | Clinical model\(^{a,b}\) | uNGAL | uNGAL + clinical model\(^{a,b}\) | \(P\) value\(^c\) | \(P\) value\(^d\) |
|--------|-----------------|-------|-------------------------------|---------------|----------------|
| Training cohort | 0.72 (0.68–0.75) | 0.73 (0.69–0.76) | 0.77 (0.73–0.80) | <0.001 | <0.001 |
| Validation cohort | 0.66 (0.61–0.71) | 0.71 (0.66–0.76) | 0.74 (0.69–0.79) | <0.001 | <0.001 |
| MAKE365 | | | | | |
| Training cohort | 0.70 (0.67–0.74) | 0.74 (0.71–0.78) | 0.77 (0.74–0.80) | <0.001 | <0.001 |
| Validation cohort | 0.64 (0.59–0.70) | 0.70 (0.65–0.75) | 0.72 (0.66–0.77) | <0.001 | <0.001 |

Table 4. AUC of clinical model with uNGAL for prediction of MAKE30 and MAKE365. \(^{a}\)Clinical model for MAKE30 is comprised of participant sex, ICU setting, AKI staging, sepsis, ischemic AKI, malignancy, persistent AKI, and chronic liver disease. \(^{b}\)Clinical model for MAKE365 is comprised of age, ICU setting, AKI staging, sepsis, malignancy, persistent AKI, and chronic liver disease. \(^{c}\)P value AUC of biomarker + clinical model compared with uNGAL. \(^{d}\)P value AUC of biomarker + clinical model compared with clinical model.

| MAKE30 | Number of patients | Number of patients with MAKE30 expected | Number of patients with MAKE30 observed | \(P\) value (Hosmer-Lemeshow test statistic)* |
|--------|-------------------|----------------------------------------|----------------------------------------|-----------------------------------------------|
| 1      | 94                | 10.9                                   | 11                                     | 5.04, \(P = 0.75\) |
| 2      | 90                | 16.9                                   | 13                                     | 9.16, \(P = 0.52\) |
| 3      | 91                | 22.8                                   | 25                                     | 11.4, \(P = 0.11\) |
| 4      | 91                | 29.4                                   | 34                                     | 13.6, \(P = 0.13\) |
| 5      | 92                | 36.2                                   | 34                                     | 16.2, \(P = 0.15\) |
| 6      | 91                | 42.6                                   | 41                                     | 18.7, \(P = 0.20\) |
| 7      | 92                | 50.9                                   | 52                                     | 20.5, \(P = 0.21\) |
| 8      | 91                | 58.3                                   | 61                                     | 24.5, \(P = 0.26\) |
| 9      | 92                | 67.2                                   | 62                                     | 27.3, \(P = 0.26\) |
| 10     | 91                | 76.8                                   | 79                                     | 31.9, \(P = 0.35\) |
| Total  | 915               | 412                                    | 412                                    | 178.1, \(P = 0.52\) |

| MAKE365 | Number of patients | Number of patients with MAKE365 expected | Number of patients with MAKE365 observed | \(P\) value (Hosmer-Lemeshow test statistic)* |
|---------|--------------------|------------------------------------------|------------------------------------------|-----------------------------------------------|
| 1       | 91                 | 18.2                                     | 18                                      | 10.9, \(P = 0.13\) |
| 2       | 91                 | 31.9                                     | 34                                      | 16.1, \(P = 0.13\) |
| 3       | 91                 | 41.3                                     | 42                                      | 19.5, \(P = 0.18\) |
| 4       | 91                 | 49.4                                     | 48                                      | 22.0, \(P = 0.21\) |
| 5       | 90                 | 55.5                                     | 56                                      | 24.0, \(P = 0.27\) |
| 6       | 91                 | 62.0                                     | 59                                      | 25.8, \(P = 0.26\) |
| 7       | 91                 | 67.6                                     | 65                                      | 27.5, \(P = 0.27\) |
| 8       | 91                 | 73.1                                     | 76                                      | 29.3, \(P = 0.32\) |
| 9       | 91                 | 77.9                                     | 82                                      | 31.5, \(P = 0.30\) |
| 10      | 90                 | 83.1                                     | 80                                      | 33.5, \(P = 0.33\) |

Table 5. Expected and observed numbers of major adverse kidney events at 1 month (MAKE30) and 1 year (MAKE365), stratified by deciles of logistic regression score (1 = lowest, 10 = highest), in the training and validation datasets. \(^{*}\)Follows a \(X^2\) distribution with 8 degrees of freedom for the training sample and 10 degrees of freedom for the validation sample.
the prediction of AKI, in particular severe stage 3 AKI and the prediction of 30-day RRT or death. The TRIBE and MAKE365 in both training and validation cohort. It must be emphasized that the clinical models alone per-
and uNGAL. The addition of uNGAL to clinical model significantly improved the risk prediction of MAKE30

tent AKI, implying that uNGAL tests were requested as early biomarkers for outcome prediction. Second, we did
reflects real world practice. Moreover, uNGAL request indications were predominantly for prediction of persis-
inclusion in our study to those with NGAL results were collected within 72 hours of suspected AKI, and this

timing between AKI onset and uNGAL measurement may be heterogeneous. To mitigate this issue, we restricted

timing of uNGAL testing and presence of confounding factors including sepsis and CKD.

The 30-day and 1-year mortality rates in our study were 28.5% and 50%, similar to those reported in western
cohorts. Previous studies have shown uNGAL levels’ association with adverse in-hospital outcomes includ-
ing mortality, which was likewise demonstrated in our study. However, there is a paucity of data contribut-
ing to the evidence base regarding associations between uNGAL and long-term renal outcomes after AKI. Coca
et al. reported the highest values of uNGAL and L-FABP were independently associated with long-term mortality
in an AKI cohort, but did not evaluate associations with renal function. Singer et al. showed that uNGAL mea-

sured at the time of AKI diagnosis was superior to creatinine levels and AKI staging in predicting long-term ESRD
or death. Our study included the largest number of patients to date, and showed an independent association
of uNGAL with short-term and long-term death, ESRD, and persistent renal dysfunction. Furthermore, a few
studies have investigated prognostic significance of uNGAL for progression of CKD in CKD cohorts. In AKI
patients, only one study explored uNGAL on ICU admission as a predictor CKD progression in MAKE-free ICU
survivors. Our study shows similar findings of uNGAL as an independent factor in AKI patients associated with

There have been few predictive models using urine biomarkers for prediction of AKI and AKI outcomes.
McMahon et al. demonstrated the addition of urinary NGAL/albumin to the clinical model modestly improved
the prediction of AKI, in particular severe stage 3 AKI and the prediction of 30-day RRT or death. The TRIBE
study showed that postoperative urine IL-18 and plasma NGAL improved AKI prediction over clinical model
alone from AUC of 0.69 to 0.76 and 0.75, respectively. In the SAPPHIRE and TOPAZ studies, a multivariate
clinical model with TIMP2-IGFBP-7 helped predict moderate-to-severe AKI within 12 hours with AROC of
0.88. Our study is the first to develop predictive model of MAKE30 and MAKE365 by using clinical models
and uNGAL. The addition of uNGAL to clinical model significantly improved the risk prediction of MAKE30
and MAKE365 in both training and validation cohort. It must be emphasized that the clinical models alone per-
formed better than uNGAL. The modest performance of uNGAL in our study maybe from the heterogeneous
timing of uNGAL testing and presence of confounding factors including sepsis and CKD.

Our study has several limitations. First, because uNGAL is ordered at the discretion of any physician, the
timing between AKI onset and uNGAL measurement may be heterogeneous. To mitigate this issue, we restricted
inclusion in our study to those with NGAL results were collected within 72 hours of suspected AKI, and this
reflects real world practice. Moreover, uNGAL request indications were predominantly for prediction of persist-
ent AKI, implying that uNGAL tests were requested as early biomarkers for outcome prediction. Second, we did
not have information of urine output, so outcomes might be underestimated by using creatinine criteria alone.
Third, we did not include patients without AKI, so the increased risk for adverse events with AKI staging was
more prominent in AKI stage 3 compared with stage 1/2. Lastly, we used random split-sampling method for inter-
nal validation, so external validation of MAKE30 and MAKE365 predictive models is further needed. Despite
these limitations, ours is a large observational study to assess the utility of NGAL for prognostic information in
real-world practice, where physicians routinely use uNGAL to facilitate their clinical decisions. In addition, our
study also evaluates NGAL measurements in the emergency room, general ward, and intensive care units, provid-
ing evidence on the usefulness of uNGAL in diverse clinical settings.

In conclusion, our current study demonstrates that significant association of uNGAL and risks for persistent
AKI, MAKE30, and MAKE365. The use of clinical models incorporating AKI severity and other predictors with
addition of uNGAL modestly improved prediction of MAKE30 and MAKE365. Determining uNGAL levels at
the time of AKI diagnosis, in addition to improving diagnostic assessment, may help in early selection of patients
who require close monitoring during hospital admission and after their stay, to prevent CKD progression, inci-
dent RRT, and death in AKI survivors.

Materials and Methods

Study design. The present study was conducted retrospectively on prospectively collected data of uNGAL
registry at King Chulalongkorn Memorial Hospital. Inclusion criteria were patients aged ≥18 years with
at least one uNGAL measurement within 72 hours of AKI onset between January 2016 and September 2017.
Two nephrologists independently adjudicated acute kidney injury (AKI) status and onset using creatinine criteria from the KDIGO guideline without knowledge of NGAL value. Patients were excluded if they had end-stage kidney disease, missing AKI status due to single measurement of serum creatinine, or unavailable outcomes at 365 days. The study protocol was approved by the Ethics Committee of Chulalongkorn University (IRB No. 037/61). Informed consent was waived by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University due to retrospective observational nature of the study and extraction of the patients’ data by an independent researcher with data deidentification. All research was performed in accordance with the international guidelines for human research protection as Declaration of Helsinki, The Belmont Report, and International Conference on Harmonization in Good Clinical Practice (ICH-GCP). The design, execution, and reporting of this study are in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) criteria.

Variables. Baseline characteristics of the patients were obtained from electronic medical records. AKI cause was adjudicated by two nephrologists by reviewing medical charts. Indication for uNGAL order was obtained from each physician at the time of request. Daily serum creatinine within the first week, at day 30, and at day 365 were obtained. For short-term outcomes, 30-day all-cause mortality, RRT, hospital length of stay, and renal recovery were recorded. For long-term outcomes, 365-day all-cause mortality, incident RRT, and readmission from all causes were collected. Mortality and renal replacement therapy were obtained from electronic in-house and national databases.

Definition. AKI was defined and staged according to KDIGO criteria. Baseline serum creatinine (SCr) was defined as the pre-admission SCr (obtained not more than 365 days prior) available from the hospital electronic records. When this value was not available, first admission SCr or the Modification of Diet in Renal Disease (MDRD) equation back-estimation was used, whichever one was lower. We defined transient AKI as an increase of SCr ≥1.5 times that of baseline within 7 days, that decreased to <1.5 times by 2 days after AKI onset. Persistent AKI was defined as an increase of SCr by 1.5 times of baseline that remained elevated after 3 days or more, or non-recovery before death.

Major adverse kidney events at 30 days (MAKE30) comprised death, incident dialysis, and doubling of SCr within 30 days. Major adverse kidney events at 365 days (MAKE365) comprised death, incident dialysis, and persistent renal dysfunction (doubling of SCr or estimated glomerular filtration rate < 50% from baseline) within 365 days. Renal recovery was defined as SCr <1.5 times of baseline and being free from RRT for 14 days. Sepsis was diagnosed in accordance with the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Chronic kidney disease (CKD) was defined as eGFR < 60 ml/min/1.73 m² on at least 2 occasions lasting for more than 3 months. CKD stages were defined according to KDIGO guidelines and based on eGFR levels. Progression of CKD stage in patients not on dialysis at study entry was determined by the last measured eGFR at 1 year in alive patients, resulting in reclassification to a more advanced stage or ESRD.

Urine chemistry and urinary NGAL. Urinary NGAL was measured at the time of AKI diagnosis by physicians’ discretion using a commercially available chemiluminescence method (Abbott, USA). Urinary Na, uric acid, and urea were also measured at the same time as uNGAL. The fractional excretion of sodium (FENa) was calculated by the formula (SCr × UNa)/(SNa × UCr). The fractional excretion of uric acid (FEuric) and fractional excretion of urea (FEurea) were calculated using the same formula.

Outcomes. The primary outcome was predictive value of uNGAL for persistent AKI compared with conventional markers including serum creatinine, FENa, FEuric, and FEurea at the onset of AKI. The secondary outcomes were association and predictive performance of uNGAL alone and in combination with clinical models for MAKE30 and MAKE365. Association of uNGAL with new-onset CKD in patients without baseline CKD and CKD progression in patients with baseline CKD were also explored.

Statistical analysis. Formal comparisons of continuous variables between groups were made by an unpaired t-test or by Mann–Whitney (Wilcoxon rank sum) test, and categorical data were compared using a Chi-Square or Fisher’s exact test, as appropriate. Univariate and multivariate logistic regression was used to compare biomarkers associated with AKI persistence, new-onset CKD, and CKD progression, in the presence of clinical characteristics. We used logistic regression in preference to survival analysis techniques because there was no censoring in our dataset. Variables were adjusted for in the multivariable model if on univariate analysis they were related to persistent AKI at P < 0.1 using backwards stepwise procedure. AROC was compared between each biomarker for prediction of persistent AKI. Thereafter, we identified factors independently associated with MAKE30 and MAKE365 with multivariate regression models. For this purpose, the study cohort was randomized into a training dataset (n = 925) to generate a model, and validation dataset (n = 397) for assessing the adequacy of model fit. We used the training set to identify factors independently associated with MAKE30 and MAKE365, using a backwards stepwise procedure and assessing Akaike information criteria (AIC) at each step. Model selection using AIC has better statistical properties compared to P-value based selection, and avoids arbitrary and inefficient selection rules based on P values. Factors assessed in univariate models included uNGAL concentration, sex, age, AKI stage, persistent AKI, the ward in which the patient had the uNGAL sample collected, if the patient’s etiology of AKI was ischemic cause, and comorbidities including malignancy, diabetes, ischemic heart disease, chronic liver disease and sepsis. We assessed the linearity of continuous covariates against the logit function, and if this assumption was not met, the variable was transformed or modelled in quartiles. Adjacent categories were collapsed together if the odds ratios and 95%CI were similar. A logarithmic transformation was applied for uNGAL to linearize the covariate against the logit function.
We used the coefficients from the final multivariable models (the natural logarithms of the odds ratios) to derive scores for every individual that can be used to estimate the probability of developing MAKE30 and MAKE365. The score can be calculated by multiplying the coefficient by the corresponding covariate value for each individual. These MAKE30 and MAKE365 scores can be then used to estimate the probability of that individual developing a major adverse kidney event within 30 or 365 days, respectively, using the following equation:

\[
\text{Probability} = \frac{e^{\text{Score}}}{1 + e^{\text{Score}}}
\]

Model adequacy was tested in several ways. First, we compared the mean scores in those who developed versus those who had not developed MAKE30 and MAK365 using an unpaired t-test. Second, we calculated the area under the Receiver Operating Characteristics Curve (AROC), as a measure of the ability of the model to discriminate between those with and without clinical outcomes\(^4\), comparing the AROC for uNGAL alone with that from the full multivariable model. Lastly, we assessed the calibration of the models in the training and validation datasets, by stratifying patients in deciles according to the MAKE30 and MAKE365 scores, and comparing the observed and expected number of events in each group using the Hosmer-Lemeshow Statistic\(^5\). Since the fit of any model is always better in the dataset used to derive the model than in the general population, we also calculated these statistics in the validation dataset to provide unbiased estimates of the model adequacy. Statistical analysis was conducted using Stata 16.0 (Statecorp, College Station, TX, USA).

Received: 29 October 2019; Accepted: 30 April 2020;
Published online: 26 May 2020

References
1. Srisawat, N. et al. The epidemiology and characteristics of acute kidney injury in the Southeast Asia intensive care unit: a prospective multicentre study. Nephrol Dial Transplant, https://doi.org/10.1093/ndt/gfx087 (2019).
2. Hoste, E. A. et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 41, 1411–1423, https://doi.org/10.1007/s00134-015-3934-7 (2015).
3. Uchino, S. et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294, 813–818, https://doi.org/10.1001/jama.294.7.813 (2005).
4. Bucala, I. D., Kirchner, H. L., Norfolk, E. R., Hartle, J. E. II & Perkins, R. M. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 81, 477–485, https://doi.org/10.1038/kji.2011.405 (2012).
5. Chawla, L. S., Amdur, R. L., Amodeo, S., Kimmel, P. L. & Palant, C. E. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 79, 1361–1369, https://doi.org/10.1038/kji.2011.41 (2011).
6. Ishani, A. et al. Acute kidney injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol. 20, 223–228, https://doi.org/10.1618/ASN.2007080837 (2009).
7. Coca, S. G. et al. First Post-Operative Urinary Kidney Injury Biomarkers and Association with the Duration of AKI in the TRIBE-AKI Cohort. PLoS One 11, e0161098, https://doi.org/10.1371/journal.pone.0161098 (2016).
8. Brown, J. R. et al. Are Urinary Biomarkers Better Than Acute Kidney Injury Duration for Predicting Readmission? Ann. Thorac. Surg. 107, 1699–1705, https://doi.org/10.1016/j.athoracsur.2019.02.005 (2019).
9. Federspiel, C. K. et al. Duration of acute kidney injury in critically ill patients. Ann. Intensive Care 8, 30, https://doi.org/10.1186/s13613-018-0374-x (2018).
10. Han, S. S. et al. Duration of acute kidney injury and mortality in critically ill patients: a retrospective observational study. BMC Nephrol. 14, 133, https://doi.org/10.1186/1471-2361-14-133 (2013).
11. Ishihara, K. et al. Association of Urinary Neutrophil Gelatinase-Associated Lipocalin With Long-Term Renal Outcomes in ICU Survivors: A Retrospective Observational Cohort Study. Shock 46, 44–51, https://doi.org/10.1097/SHK.0000000000000580 (2016).
12. Soca, S. G. et al. Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J. Am. Soc. Nephrol. 25, 1063–1071, https://doi.org/10.1681/ASN.2013070742 (2014).
13. Koyner, J. L. et al. Tissue Inhibitor of Metalloproteinase-2 (TIMP-2)IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. J. Am. Soc. Nephrol. 26, 1747–1754, https://doi.org/10.1681/ASN.2014060556 (2015).
14. Cruz, D. N. et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. 36, 444–451, https://doi.org/10.1007/s00134-009-1711-1 (2010).
15. de Geus, H. R., Bakker, J., Lesaffre, E. M. & de Noble, J. L. Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am. J. Respir. Crit. Care Med. 183, 907–914, https://doi.org/10.1164/rccm.200908-1214OC (2011).
16. Bagshaw, S. M. et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 36, 452–461, https://doi.org/10.1007/s00134-009-1724-9 (2010).
17. Mishra, J. et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365, 1231–1238, https://doi.org/10.1016/S0140-6736(05)6811-X (2005).
18. Nickolas, T. L. et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J. Am. Coll. Cardiol. 59, 246–255, https://doi.org/10.1016/j.jacc.2011.10.854 (2012).
19. Singer, E. et al. Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes. J. Am. Soc. Nephrol. 80, 403–414, https://doi.org/10.1038/ki.2011.41 (2011).
20. Srisawat, N. et al. Plasma neutrophil gelatinase-associated lipocalin predicts recovery from acute kidney injury following community-acquired pneumonia. Kidney Int. 80, 545–552, https://doi.org/10.1038/ki.2011.160 (2011).
21. Parihk, C. et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J. Am. Soc. Nephrol. 22, 1748–1757, https://doi.org/10.1681/ASN.2010121302 (2011).
22. Kumpers, P. et al. Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit. Care 14, R9, https://doi.org/10.1186/cc861 (2010).
23. Singer, E. et al. Urinary NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients. Kidney Int. Rep. 1, 114–124, https://doi.org/10.1016/j.ekir.2016.07.003 (2016).
24. McMahon, T. A. et al. Biomarker Predictors of Adverse Acute Kidney Injury Outcomes in Critically Ill Patients: The Dublin Acute Biomarker Group Evaluation Study. Am. J. Nephrol. 50, 19–28, https://doi.org/10.1159/000480231 (2019).
25. Siew, E. D. et al. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J. Am. Soc. Nephrol. 20, 1823–1832, https://doi.org/10.1681/ASN.2008070673 (2009).
26. Uchino, S., Bellomo, R., Bagshaw, S. M. & Goldsmith, D. Transient azotemia is associated with a high risk of death in hospitalized patients. Nephrol. Dial. Transpl. 25, 1833–1839, https://doi.org/10.1093/ndt/gpj624 (2010).
27. Susantiphong, P. et al. World incidence of AKI: a meta-analysis. Clin. J. Am. Soc. Nephrol. 8, 1482–1493, https://doi.org/10.2215/cjn.00710113 (2013).
28. Lafrance, J. P. & Miller, D. R. Acute kidney injury associates with increased long-term mortality. J. Am. Soc. Nephrol. 21, 345–352, https://doi.org/10.1681/asn.2009060836 (2010).
29. Coca, S. G., Yusuf, B., Shlipak, M. G., Garg, A. X. & Parikh, C. R. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Diseases: Off. J. Natl Kidney Found. 53, 961–973, https://doi.org/10.1053/j.ajkd.2008.11.034 (2009).
30. Bennett, M. et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin. J. Am. Soc. Nephrol. 3, 665–673, https://doi.org/10.2215/CJN.04010907 (2008).
31. Nickolas, T. L. et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann. Intern. Med. 148, 810–819, https://doi.org/10.7326/0003-4819-148-11-20080630-00003 (2008).
32. Yang, H. N. et al. Urine neutrophil gelatinase-associated lipocalin: an independent predictor of adverse outcomes in acute kidney injury. Am. J. Nephrol. 31, 501–509, https://doi.org/10.1159/000309841 (2010).
33. Dori, M., Morita, K., Mantrarajus, H., Sato, S. & Kenny, G. N. Prediction of responses to various stimuli during sedation: a comparison of three EEG variables. Intensive Care Med. 31, 41–47, https://doi.org/10.1007/s00134-004-2516-x (2005).
34. Huelin, P. et al. Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology 70, 319–333, https://doi.org/10.1002/hep.30592 (2019).
35. Hamdy, H. S. et al. Urinary Neutrophil Gelatinase-Associated Lipocalin in Cirrhotic Patients with Acute Kidney Injury. Ann. Hepatol. 17, 624–630, https://doi.org/10.5604/01.3001.2012.0931 (2018).
36. Liu, K. D. et al. Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int. 83, 909–914, https://doi.org/10.1016/j.kid.2012.458 (2013).
37. Lobato, G. R., Lobato, M. R., Thome, F. S. & Veronese, F. V. Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-beta-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes. Braz. J. Med. Biol. Res. - Rev. brasileira de. Pesqui. medicas e biologicas 50, e6106, https://doi.org/10.1590/1414-431x20171606 (2017).
38. Zhou, L. T. et al. Are Urinary Tubular Injury Markers Useful in Chronic Kidney Disease? A Systematic Review and Meta Analysis. PLoS One 11, e0167334, https://doi.org/10.1371/journal.pone.0167334 (2016).
39. Gunnerson, K. J. et al. TIMP2-IGFBP7 biomarker panel accurately predicts acute kidney injury in high-risk surgical patients. J. Trauma. Acute Care Surg. 80, 243–249, https://doi.org/10.1097/TA.0000000000001912 (2016).
40. Kellum, J. A. et al. Classifying AKI by Urine Output versus Serum Creatinine Level. J. Am. Soc. Nephrol. 26, 2231–2238, https://doi.org/10.1681/ASN.2014070724 (2015).
41. Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 120, c179–184, https://doi.org/10.1159/000339789 (2012).
42. World Medical Association Declaration of Helsinki, ethical principles for medical research involving human subjects. Jama 310, 2191–2194, https://doi.org/10.1001/jama.2013.281053 (2013).
43. Paradisid, E., Pike, E. & McGraw, D. A Belmont Report for Health Data. The. BMJ Open 1, 1–4, https://doi.org/10.1136/bmjopen-2011-000182 (2011).
44. van Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann. Intern. Med. 147, 573–577, https://doi.org/10.7326/0003-4819-147-8-200710160-00010 (2007).
45. Collins, G. S., Reitma, J. B., Altman, D. G. & Moons, K. G. Transparent Reporting of a multivariable prediction model for Individual Needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8, R204-209, https://doi.org/10.1186/cc5007 (2004).
46. De Rosa, S., Samoni, S. & Ronco, C. Creatinine-based definitions: from baseline creatinine to serum creatinine adjustment in intensive care. Crit. Care 20, 69, https://doi.org/10.1186/s13054-016-1218-4 (2016).
47. Pertiel, S. et al. Transient and Persistent Acute Kidney Injury and the Risk of Hospital Mortality in Critically Ill Patients: Results of a Multicenter Cohort Study. Crit Care Med 43, e269-275, doi:10.1097/CCM.0000000000001077 (2015).
48. Chawla, L. S. et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 13, 241–257, https://doi.org/10.1038/nrneph.2017.2 (2017).
49. Rhodes, A. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 43, 304–377, https://doi.org/10.1007/s00134-017-4863-8 (2017).
50. Stevens, P. E. & Levin, A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825–830, https://doi.org/10.7326/0003-4819-158-11-20130604-00007 (2013).
51. Harrell Frank E., J. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. (Springer-Verlag. New York, Inc. (2001).
52. Cook, N. R. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin. Chem. 54, 17–23, https://doi.org/10.1373/clinchem.2007.096529 (2008).
53. Hosmer, D. W., Hosmer, T., Le Cessie, S. & Lemeshow, S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 16, 965–980, 10.1002/(sici)1097-0258(19970515)16:9<965::aid-sim509>3.0.co;2-o (1997).

Acknowledgements
The authors would like to thank Miss Pinnara Peerawaranun for help in statistical analysis and all staff at Division of Nephrology, Chulalongkorn University and Excellence Center for Critical Care Nephrology for their support.

Author contributions
N.L. performed the data analysis, interpretation of data, and wrote the manuscript. N.S. provided the study design, data interpretation, and revision of the manuscript. M.A., S.T., J.D., and S.P. helped in data collection and interpretation of data. S.J.K. helped in data analysis and manuscript revision. All authors approved the final version of the manuscript to be published.

Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65764-w.

Correspondence and requests for materials should be addressed to N.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020